- Home
- BBIO
as 12-20-2024 4:00pm EST
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | 5.1B | IPO Year: | 2019 |
| Target Price: | $47.92 | AVG Volume (30 days): | 2.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $21.62 - $44.32 | Next Earning Date: | 11-12-2024 |
| Revenue: | $217,765,000 | Revenue Growth: | 2209.77% |
| Revenue Growth (this year): | 2648.47% | Revenue Growth (next year): | -25.47% |
Stock Insider Trading Activity of BridgeBio Pharma Inc. (BBIO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kumar Neil | BBIO | Chief Executive Officer | Nov 19 '24 | Sell | $22.57 | 27,389 | $613,825.89 | 4,899,318 | |
| STEPHENSON BRIAN C | BBIO | Secretary, Treasurer & CFO | Nov 19 '24 | Sell | $22.41 | 4,156 | $93,136.79 | 93,758 |
Latest BridgeBio Pharma Inc. News
BBIO Breaking Stock News: Dive into BBIO Ticker-Specific Updates for Smart Investing
MT Newswires
9 days ago
BridgeBio's Acoramidis Recommended by EU Panel for Transthyretin Amyloid Cardiomyopathy
GlobeNewswire
9 days ago
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Zacks
22 days ago
Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More
Zacks
a month ago
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug
Zacks
a month ago
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use
Morningstar Research
a month ago
Analyst Report: BridgeBio Pharma, Inc.
TipRanks
a month ago
BridgeBio price target raised to $45 from $42 at BofA
MT Newswires
a month ago
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading
Compare BBIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BBIO BridgeBio Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.